Venous thromboembolism, particularly deep vein thrombosis (DVT), is often complicated by the development of post-thrombotic syndrome (PTS) or pulmonary embolism. To prevent PTS, an early thrombus removal strategy using interventional techniques-catheter-directed thrombolysis (CDT), pharmacomechanical thrombolysis (PMT), ultrasound-accelerated thrombolysis, and thrombectomy-is considered. The efficacy of these methods has been investigated in large randomized controlled trials and meta-analyses, which have shown that although interventions do not reduce the overall incidence of PTS in the general population, they significantly decrease the risk of moderate and severe PTS in carefully selected patients with acute iliofemoral DVT. At the same time, these interventions are associated with an increased risk of major bleeding compared with anticoagulant therapy alone. The aim of this review was to analyze the efficacy and safety of CDT and PMT in the treatment of acute iliofemoral DVT and to formulate principles for personalized patient selection for interventional treatment, taking into account contemporary data on quality of life and cost-effectiveness. Research methodology: Literature search was conducted in the databases PubMed, Embase, Cochrane Library, Scopus, Web of Science and ClinicalTrials.gov for the period from January 2019 to December 2025. The results of the research: The review included randomized clinical trials ATTRACT, CaVenT, CAVA, as well as prospective cohort studies and meta-analyses Chen, Li, Tian, Wang, Liu, Turner, covering a total of more than 7,000 patients with acute proximal, predominantly iliofemoral DVT. CT and FMT cannot be considered a universal standard for all patients, but play an important role in a limited, clearly defined population. Modern pharmacomechanical devices (AngioJet, etc.) allow you to achieve a better efficiency-safety balance than traditional KTL, especially in centers with high technical equipment and experience. Conclusion: Pharmacomechanical technologies demonstrate superiority over classical CTL in key anatomical and clinical outcomes – recanalization, PTS control, severity of pain syndrome and duration of hospitalization – with a more favorable safety profile due to a decrease in the dose and time of exposure to thrombolytic.